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The genes for the E2 envelope protein, which elicits virus-neutralizing antibodies, from members of the newly described
group II of bovine viral diarrhea viruses (BVDVs) were cloned and sequenced. These BVDVs included a thrombocytopenic
strain from the United States, a fetal bovine serum contaminant, a strain from Western Canada, and two highly virulent
strains, causing high mortality rates, from Quebec. The nucleotide and amino acid sequences of these E2s had only a 60–
65% homology with group I BVDV E2s but 90% homology with the E2 of a subgroup of sheep border disease viruses.
The E2 gene of the NADL strain was expressed and monospecific antibodies were raised in calves and rabbits. The virus-
neutralizing titers of these antisera were 15- to 80-fold lower for the heterologous group of BVDVs as compared to those
for the homologous BVDVs. q 1996 Academic Press, Inc.
Bovine viral diarrhea virus (BVDV) is a ubiquitous serological crossreactivity (19), associated with severe
pathogen of cattle causing important economic losses. outbreaks and high mortalities among veal calves (up to
It is classified in the Pestivirus genus of the Flaviviridae 25% mortality in Quebec). Ridpath et al. (20) reported a
(1) along with border disease virus (BDV) strains of sheep similar segregation of BVDV groups using essentially the
and classical swine fever virus (CSFV) strains of pigs. same approach (5*-UTR analysis and serology). Interest-
Although these names suggest that pestiviruses are con- ingly, sequences of pestivirus RNAs, which were found
fined to their host, numerous examples have been re- to contaminate human vaccines, closely resemble those
ported of cross-infection among cattle, sheep, other of the newly recognized, virulent BVDVs (19, 21).
ruminants, and pigs (2 – 9) and indicate the necessity of Pestiviruses contain a positive-sense RNA of about
caution in laboratory diagnostic methods. Cross- 12.5 kb, which has one large open reading frame coding
neutralization with polyclonal antisera and MAbs re- for a polyprotein of approximately 4000 amino acids (22–
vealed that CSFV strains can be easily distinguished from 24). The structural and nonstructural proteins are co- and
the ruminant pestiviruses, BDV and BVDV, but that the posttranslationally cleaved from polyprotein precursors
latter form a heterogenous group (10, 11). Sequencing of (25, 26). The three viral envelope-associated glycopro-
structural proteins of BDV isolates (12) and the use of teins, named E0 (gp48), E1 (gp25), and E2 (gp53) in order
MAbs on BDV field isolates (13) indicated the existence of their arrangement near the N-terminal of the polypro-
of two and three subgroups of BDV, respectively. tein, are cleaved after translocation into the lumen of the
Apart from mucosal disease, to which persistently in- endoplasmic reticulum (ER) (27). Although antibodies that
fected animals may succumb, BVDV generally causes a neutralize virus infectivity are directed to epitopes on
mild diarrhea followed by the appearance of neutralizing both the E0 and E2, E2 is by far the immunodominant
antibodies with a rapid recovery (14). Other clinical mani- protein (28, 29). In contrast, E1 is believed to be buried
festations may include abortion, teratogenesis, and res- in the viral envelope (30) and to be hardly accessible.
piratory problems. In addition, severe thrombocytopenia, Nevertheless, heterodimers of E1 with E2 are found in
associated with herd epidemics, that may result in the addition to the homodimers of E2 (27, 31). The proteolytic
death of the animal has been described (15–17) and cleavages between E1 and E2 and between E2 and the
strains associated with this disease seem more virulent p125 are most likely mediated by host cell signalases in
than the classical BVDVs (18). Last year, we identified a the lumen of the ER (27). The C-terminus of the E2 is
new group of BVDVs, based on 5*UTR sequences and very hydrophobic and could function as a stop–transfer
signal for E2 (32) and probably constitutes one or more
membrane-spanning anchors as well (27).1 To whom reprint requests should be addressed.
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In the present study, we analyzed the E2 of group II scriptase or Taq polymerase, at least three independent
clones were sequenced for each strain. Computer analy-BVDVs of different origins with respect to their se-
quences and serological crossreactivities with E2 of sis of sequence data was carried out with the PCGene
(Intelligenetics) and UWGCG software.NADL (group I BVDV). For this purpose, we selected one
isolate from Western Canada (1494); one isolate associ- The nucleotide sequences of these group II BVDV E2s
have been submitted to GenBank (accession No. U44g56ated with thrombocytopenia in the United States (CD87,
kindly supplied by Dr. E. J. Dubovi, Cornell University, (Q140), U44908 (Q4812), U44907 (CD87), U44906 (SF4)
and U44905 (1494)) and have been compared to E2s fromIthaca, NY); one isolate from fetal bovine serum, which
has probably been the route of contamination of human group I BVDVs NADL (23), SD-1 (37), and Osloss (22).
The E2 sequences for Oregon (29) and Singer (38) werevaccines noted above (SF4); and two isolates of BVDVs
associated with severe outbreaks and high mortalities completed (Genbank accession No. L35851 and L35852).
Overlaps with the previously published Oregon andamong calves in Quebec (kindly provided by Ministe`re
de l’Agriculture, des Peˆcheries et de l’Alimentation du Singer E2 sequences differed 1%. The E2 nucleotide
sequence homology between the groups I and II ofQue´bec (MAPAQ) at Institut Armand-Frappier: Q140
(case 93-581, a nursing calf) and Q4812 (case 93-1233, BVDVs was only 60–65%, whereas the sequence homol-
ogies within group II were 90% (Table 1). The E2 se-a veal calf). These five BVDVs represent different
branches of the group II dendrogram (19). Our results on quence homology between the NADL/SD-1/Singer/Ore-
gon group and Osloss within group I is also low (70–the immunodominant E2 protein of these strains provide
strong evidence that the virulent group II BVDVs are 75%) since these strains are found in the two different
branches of the group I dendrogram (19) which, tenta-closely related to a subgroup of BDVs of sheep and that
pestiviruses have to be reclassified, a conclusion that tively, have been named group Ia and Ib (both group I
since no major serological differences were observed).complements the one reached independently by Becher
et al. (33) by analysis of the nonstructural Npro and the This dichotomy in group I BVDV genotypes was also
confirmed by sequencing the complete p125 of severalnucleocapsid C proteins. These studies on the immuno-
dominant structural protein confirm the classification group I strains (39). Although the laboratory strains used
in this study are from group Ia, most of the current fieldsuggestions by Pellerin et al. (19) and Ridpath et al. (20).
Viral RNA was extracted from infected MDBK cell su- isolates in Quebec are found in Ib (19, 40). The predicted
E2 amino acid sequences of the group II BVDV strainspernatants following the methods described previously
(19). MDBK cells were grown in MEM (Gibco/BRL) sup- were compared to those of group Ia strains (NADL,
Singer, SD-1 and Oregon (23, 29, 37, 38)), of a group Ibplemented with horse serum. Cells and media used for
culture were free of contaminating BVDV. After precipita- strain (Osloss (22)), of an ovine BDV strain (BD-78 (41)),
of ‘‘true’’ BDV strains (X818 and L83/84 (12)) and of CSFVtion, the RNA was resuspended in DEPC-treated water.
This RNA was reverse-transcribed into cDNA by a slight strains (Alfort, Brescia, and Weybridge (42–44) (Fig. 1).
The group II BVDV sequences closely resembled thosemodification of the previously described method (19) by
including a 5-min 947 step after the reverse transcription of BD-78 (representative of a subgroup of BDV). The C-
terminal half of the E2 (amino acids 201–370) tended tostep to inactivate the MMuLV-reverse transcriptase non-
template polymerase activity (34) which improved consid- be more conserved (49% identity for these 16 pestivi-
ruses) than the N-terminal half (amino acids 1–200, 28%erably the subsequent PCR. Several primers, with se-
quences based on conserved regions in the pestiviruses, identity) where most of the immunodominant epitopes
are located (29, 38). These alignments indicated alsowere synthesized and those that performed best are indi-
cated in the legend of Fig. 1. A set of amplicons was that, according to the degree of sequence identity, at
least four pestivirus groups can be distinguished (Fig. 2).obtained for each strain, one of about 1.1 kb and one of
about 1.3 kb, both of which started about 120 nt upstream The cleavage sites at the N-terminus of E2 (27) were
also found to be highly conserved for group II BVDVsof the expected start of E2. The shorter amplicon was
expected to lack the sequence for the hydrophobic mem- and the upstream sequences conform to the rules pro-
posed by von Heijne (45) for cleavages by host cell sig-brane anchor and stop– transfer signal. PCR products
were cloned into the pCRII vector (InVitrogen) according nalases.
The maintenance of noncytopathic (ncp) strains re-to the manufacturer’s recommendations. Ten percent (1
ml) of the ligation product was then used to transform mains problematic. In a previous study we observed that
one of two NY-1 published sequences was a sequenceXL1-Blue cells (Stratagene) according to standard meth-
ods (35). The cloned amplicons were sequenced by the of another virus (39). This study raised a similar problem.
Although previous studies indicated that sequences of thedideoxy method (36) using the AutoRead and AutoCycle
sequencing kits (Pharmacia) and the Automated Laser Singer ncp strain are closely related to those of ovine
pestiviruses (i.e., the group II subgroup; cited in Ref. 33),Fluorescent DNA sequencer. The sequences of the inter-
nal primers are given in the legend of Fig. 1. Due to our results with the E2 of the cp Singer strain clearly
demonstrated that it is a classical BVDV. This apparentpossible erroneous incorporation by reverse tran-
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FIG. 1. Amino acid sequence of E2s of pestiviruses compared to that of the Osloss strain. Two sequences (Singer, Oregon) of the classical
BVDVs (grouped as A) and five sequences of group II BVDVs (grouped as B) were completed and compared to those of BD-78 (an ovine pestivirus),
of ‘‘true’’ BDVs of sheep (grouped as C) and of CSFV of swine (grouped as D). The E2 sequences were clearly different between groups but
resembled each other strongly within the groups. Part of E1, preceding E2 and containing the stop–transfer and the translocation signals (27), is
also shown. These genes were amplified using primers pII-251 (TAACWNGSATWTGGAACSCTGC) and the reverse complement of CAGAGTTCATAG-
TYATAGCRGT (pII-350), yielding a fragment of 1.1 kb, or BVII (CAGAGATCTTCATAGCAAGTTGCCCATCAT), yielding a 1.3-kb fragment (cycling
conditions 947 for 1 min, 507 for 1.5 min, 727 for 2.5 min; 35 cycles). Primer-walking sequencing was achieved with primers BII-281 (CTTT GGACTCTGC-
CCTTG), BII-300 (CAATCTGGACTGGTC), BII-311 (CAAGAAGTGTAAGTGGTGTG), BII-316 (TGTCTGTACCCACTCTC), BII-324 (CTATGGCWACAC-
CCCT), and BII-337 (ATAAGTATTATGAGCCAAG).
contradiction can be explained by assuming that in these Quebec virulent strains with the calf serum and ovine
(BD-78) viruses being intermediate (Table 1, Fig. 2).other studies, during cell passage, the original Singer virus
has been contaminated by a group II pestivirus present The crossreactivity of monospecific antibodies, raised
to NADL E2, to these group II BVDV E2s was also investi-in fetal calf serum (like the SF4 virus we isolated from
serum). Such a contaminant is not easily detected by se- gated to establish whether these sequence differences
translated into significant serological differences. This isrology, particularly if present at low titers (see below).
Although nucleotide and amino acid sequence differ- particularly relevant for the current effort in the develop-
ment of E2 subunit vaccines. Recombinant vaccinia wasences were minor within group II BVDV E2s, they tended
to be most pronounced between 1494/CD87 and the found convenient for the expression and purification of
AID VY 7721 / 6a10$$$142 02-05-96 13:14:12 vira AP: Virology
359SHORT COMMUNICATION
FIG. 1 —Continued
E2 from NADL and its use for the production of monospe- Deregt, Animal Disease Research Institute, Lethbridge,
Alberta, Canada). Full-length E2 was extracted from in-cific antibodies (van den Hurk et al., unpublished results).
In short, PCR on NADL cDNA, with primers designed to fected BSC-1 cells. The harvested cells were centrifuged
at 1500 g for 10 min in 10 mM Tris–HCl, 150 mM NaCl,amplify a full-length E2 between amino acids 665 (Phe)
and 1063 (Lys) and BglII endonuclease sites near their pH 7.5, containing 1% Nonidet P-40 (NP-40) and 1% deox-
ycholate. The supernatant was then subjected to an ultra-5*-ends, yielded a 1.25-kb product which was cloned into
the unique BglII site of pVVSLI. The insert in the vaccinia centrifugation for 60 min at 80,000 g. The resulting super-
natant was passed three times through an affinity columnvector was then transferred into vaccinia virus (WR strain)
by homologous recombination in LMTK0 cells and re- (5 mg/ml MAb coupled to AFFIGEL-10 (Pharmacia) ac-
cording to the manufacturer’s recommendations) and un-combinant viruses were selected as described pre-
viously (46). The recombinant vaccinia viruses express- bound material washed with a buffer containing 10 mM
Tris–HCl, 500 mM NaCl, 0.1% NP-40 (pH 7.5). E2 wasing recombinant proteins, as determined by immunoper-
oxidase staining (47), were plaque-purified (48). The eluted with 50 mM diethylamine, pH 11.5, neutralized
with Tris–HCl, concentrated on an Amicon YM10 mem-expressed E2 was purified by immunoaffinity chromatog-
raphy using MAb 450-19 to E2 (kindly provided by Dr. D. brane and dialyzed against PBS. The quality of E2 was
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TABLE 1
Matrix of Pairwise E2 Nucleotide Sequence Similarity Scores of Groups I and II BVDVs
Group I BVDVs Group II BVDVs
NADL Singer Oregon SD-1 1494 Q140 Q4812 SF4 CD87 BD-78
Osloss 72.9 72.0 74.9 73.7 60.8 64.0 64.5 65.0 62.9 63.5
NADL 94.1 85.6 84.7 63.8 65.2 65.6 64.8 65.1 64.1
Singer 85.0 84.8 64.5 63.5 64.2 63.7 64.6 62.6
Oregon 89.1 64.3 62.6 64.2 63.8 64.9 62.6
SD-1 64.4 63.3 63.6 63.6 63.1 61.3
1494 90.6 90.3 90.5 89.4 91.7
Q140 98.8 96.3 89.9 95.5
Q4812 95.9 89.6 95.1
SF4 89.4 94.5
CD87 90.3
then ascertained by SDS–PAGE under reducing and raised against the whole virus, that group I and group II
BVDVs can be serologically distinguished (titer at leastnonreducing conditions and by Western blotting. Mono-
specific sera against affinity-purified E2 were obtained 4-fold higher against strains from the same group). In
this experiment with monospecific antibodies against E2,by immunization of both calves and rabbits. The proteins
were mixed with avridine as an adjuvant and adminis- the difference in VN titers between the two groups was
15- to 80-fold (Table 2). In addition, the immunoperoxi-tered intramuscularly twice with an interval of 3 weeks.
Virus neutralization (VN) assays were carried out in dase staining intensity was much weaker in cells in-
fected with group II viruses. NS3 (p80) proteins, whichquadruplicate as described previously (19). The neutraliz-
ing titer was the reciprocal value of the highest serum during a normal infection elicit high antibody titers (even
when pigs are infected with classical BVDVs), have adilution giving a 100-fold reduction in virus titer. Pre-
viously (19), we observed, using strain-specific antisera highly conserved sequence (39, 49) and thus may ob-
scure serological differences among pestivirus groups.
Consequently, E2 subunit vaccines are expected to
be much more group-specific than live vaccines using
the same strains. Monospecific group II E2 antibodies
have not been raised but are expected to have a similar
preferential affinity for the homologous viruses as was
shown previously with antisera to whole group I and II
viruses (19).
TABLE 2
BVDV Titers in Sera from Cows and Rabbits Immunized
with E2 from NADL
Virus (group/strain) VN titers (calves)a VN titers (rabbits)b
Group I
NADL 32,000 36,000
Oregon 12,000 24,000
Singer 24,000 24,000
Group II
Q140 800 500
Q4812 800 750
1494 800 750FIG. 2. Dendritic comparison of E2 amino acid sequences from Fig.
1 using the GCG PileUp program. The top branch is split into CSFV SF4 400 400
CD87 400 1,000and ‘‘true’’ BDV groups whereas the homology between group II and
group I BVDVs (in the bottom branch) seemed even less (similar to
dendritic observation for Npro autoprotease of these virus groups; 33). a Mean BVDV neutralizing antibody titers in sera from six calves after
two immunizations with affinity-purified E2.Within group I, Osloss occupies (as for other parts of its genome; 19,
38) a distinct branch (Ib). (Horizontal branch lengths are proportional b Mean BVDV neutralizing antibody titers in sera from two rabbits
after two immunizations with affinity-purified E2.to sequence similarity).
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